Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy
Robert A. Henderson, FRCP, FESC*,*,
Stuart J. Pocock, PhD ,
Tim C. Clayton, MSc,
Rosemary Knight, RGN,
Keith A. A. Fox, FRCP, FESC ,
Desmond G. Julian, FRCP, FESC ,
Douglas A. Chamberlain, FRCP, FESC|| Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants
* Nottingham City Hospital, Nottingham, United Kingdom
London School of Hygiene and Tropical Medicine, London, United Kingdom
Royal Infirmary, Edinburgh, United Kingdom
London, United Kingdom
|| Pre-hospital Emergency Research Unit and Wales Heart Institute, University of Wales College of Medicine, Cardiff, United Kingdom
View larger version (19K):
[in a new window]
|
Figure 1 Cumulative risk of (A) death and (B) death or definite non-fatal myocardial infarction (MI). Bars show 95% confidence interval. Numbers show patients at risk of death or non-fatal MI. PTCA = percutaneous transluminal coronary angioplasty.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Non-randomized intervention rates by year of follow-up. CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty.
|
|
View larger version (31K):
[in a new window]
|
Figure 3 Prevalence of angina over time at baseline (base), three, and six months, and yearly intervals after randomization. P = coronary angioplasty group; M = medical group.
|
|
View larger version (61K):
[in a new window]
|
Figure 4 Mean angina grades before and after non-randomized intervention. Panels A and B show data for the percutaneous transluminal coronary angioplasty (PTCA) group. Panels C and D show data for the medical group. Lines are smoothed averages and 95% confidence intervals. The circles show individual data points. Continued on next page. For the medical group (C and D), the triangle indicates angina grade immediately before non-randomized intervention. CABG = coronary artery bypass graft.
|
|
|
